Nyxthracis (previously Obiltoxaximab SFL) Euroopa Liit - ungari - EMA (European Medicines Agency)

nyxthracis (previously obiltoxaximab sfl)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - immunrendszer sera, immunglobulinok, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

Melatonin Neurim Euroopa Liit - ungari - EMA (European Medicines Agency)

melatonin neurim

rad neurim pharmaceuticals eec sarl - melatonin - alvási beavatkozás és karbantartás - pszicholeptikumok - melatonin neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.

Mycapssa Euroopa Liit - ungari - EMA (European Medicines Agency)

mycapssa

amryt pharmaceuticals dac - octreotide acetate - acromegalia - hipofízis és hypothalamus hormonok és analógok - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

Pedmarqsi Euroopa Liit - ungari - EMA (European Medicines Agency)

pedmarqsi

fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - minden más terápiás készítmény - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.

Refludan Euroopa Liit - ungari - EMA (European Medicines Agency)

refludan

celgene europe ltd. - lepirudint - thromboembolism; thrombocytopenia - antitrombotikus szerek - felnőtt betegek ii-es típusú heparin indukálta thrombocytopenia és thromboemboliás betegség megbízási parenterális antithrombotic kezelés antikoaguláns. a diagnózist meg kell erősíteni a heparin indukálta thrombocyta aktiváló vizsgálat, vagy egy ezzel egyenértékű vizsgálat.